case_images: PMC10869147_01
case_images: Clinical course of the patient. Although induction therapy aided in blast cell reduction, it did not result in complete remission (CR) phenotypically. Following consolidation therapy and salvage chemotherapy with nelarabine, hematological progression but not CR was slowed. A trial with GO to induce remission was unsuccessful in the patient's leukemia cells. GO, gemtuzumab ozogamicin.
case_images: cro-2024-0017-0001-536424_F01.jpg
case_images: PMC10869147_01_cro-2024-0017-0001-536424_F01.jpg
case_images: F1
case_images: At 33 days after GO treatment, the patient's bone marrow showed 40% leukemic progression (a clinical course is shown in Fig. 1), with CD33 molecules still strongly expressed.